A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. [electronic resource]
Producer: 20151015Description: 572-9 p. digitalISSN:- 1439-7609
- Adalimumab
- Age Factors
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antirheumatic Agents -- adverse effects
- Arthritis, Rheumatoid -- drug therapy
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Etanercept
- Female
- Humans
- Immunoglobulin G -- adverse effects
- Incidence
- Japan -- epidemiology
- Male
- Middle Aged
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Registries
- Republic of Korea -- epidemiology
- Risk Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.